Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;60(8):1032-1033.
doi: 10.1111/ijd.15623. Epub 2021 Apr 30.

Leukocytoclastic vasculitis flare following the COVID-19 vaccine

Stephanie R Cohen  1 , Lisa Prussick  1 , Jared S Kahn  1 , David X Gao  1 , Arash Radfar  2 , David Rosmarin  1
Affiliations

Leukocytoclastic vasculitis flare following the COVID-19 vaccine

Stephanie R Cohen et al. Int J Dermatol. 2021 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histopathologic photomicrographs, H&E stain: Sections show a perivascular mixed inflammatory infiltrate with numerous neutrophils, lymphocytes, and occasional eosinophils. There is leukocytoclasia and erythrocyte extravasation, but fibrinoid necrosis of vessels is not observed. (a) Magnification at ×4, (b) magnification at ×10, and (c) magnification at ×40
Figure 2
Figure 2
(a) Leukocytoclastic vasculitis after first dose of COVID‐19 vaccine. Palpable purpuric papules distributed on bilateral lower legs. (b) Leukocytoclastic vasculitis after second dose of COVID‐19 vaccine. Widespread palpable purpuric papules and plaques distributed on bilateral legs and feet. (c) Leukocytoclastic vasculitis after second dose of COVID‐19 vaccine. Closer look to widespread palpable purpuric papules and plaques located on the right lateral anterior lower leg
See this image and copyright information in PMC

References

    1. U.S. Food and Drug Administration . Infectious Disease Coronavirus. 2021. Pfizer‐BioNTech COVID‐19 Vaccine. https://www.fda.gov/emergency‐preparedness‐and‐response/coronavirus‐dise.... Accessed on 16 January 2021.
    1. Bonetto C, Trotta F, Felicetti P, et al. Vasculitis as an adverse event following immunization – systematic literature review. Vaccine 2016; 34: 6641–6651. - PubMed
    1. Vojdani A, Kharrazian D. Potential antigenic cross‐reactivity between SARS‐CoV‐2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol 2020; 217: 108480. - PMC - PubMed
    1. Gresham LM, Marzario B, Dutz J, et al. An evidence‐based guide to SARS‐CoV‐2 vaccination of patients on immunotherapies in dermatology. J Am Acad Dermatol 2021; S0190‐9622(21)00196‐1. 10.1016/j.jaad.2021.01.047 - DOI - PMC - PubMed

MeSH terms

Substances

Supplementary concepts